explore -WSS

explore

author：explore 2025-09-05 11:19:26 - browse：92465

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： GSK Flovent asthma inhalers replaced by authorized generics

WSS

Diverse clinical trials: Why aren’t we there yet?

Chronically ill young patients struggle to find fertility info

Generate Biomedicines machine learning biotech raises $273M

How a scoliosis diagnosis changed the life of one young dancer

Pig kidney works a record two months in donated body

Long Covid needs a new name — and a new frame

explore

explore

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House finalizes ITC's import ban of latest Apple Watches

DIEP, the 'gold standard' of breast reconstruction, is under threat

GSK Flovent asthma inhalers replaced by authorized generics

Hepatitis C has a cure — but many Americans still lack access to it

U.K. sequencing study surfaces new findings about tumor DNA

As demand for Covid shots wanes, Moderna seeks its next success

Antibiotic resistance and the global rise in human conflict

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

focus

How a scoliosis diagnosis changed the life of one young dancer

UCB departs biotech trade group BIO

Videos point to link between seizures and unexplained toddler deaths

New Covid vaccine is recommended for everyone 6 months or older

New weight loss drugs vying to be the next Wegovy or Mounjaro

FDA proposes changes to key medical devices approval pathway

focus

focus

hotspot

knowledge